Comparison of sIgG4 levels among allergic patients and patients during ASIT
G. Feyzkhanova (Moscow, Russian Federation), O. Smoldovskaya (Moscow, Russian Federation), S. Voloshin (Moscow, Russian Federation), L. Pavlushkina (Moscow, Russian Federation), E. Antonova (Moscow, Russian Federation), T. Filatova (Moscow, Russian Federation), A. Zasedatelev (Moscow, Russian Federation), A. Rubina (Moscow, Russian Federation)
Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Feyzkhanova (Moscow, Russian Federation), O. Smoldovskaya (Moscow, Russian Federation), S. Voloshin (Moscow, Russian Federation), L. Pavlushkina (Moscow, Russian Federation), E. Antonova (Moscow, Russian Federation), T. Filatova (Moscow, Russian Federation), A. Zasedatelev (Moscow, Russian Federation), A. Rubina (Moscow, Russian Federation). Comparison of sIgG4 levels among allergic patients and patients during ASIT. 1139
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Serum levels of interleukin-1α in patients affected by atopic and non atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 290s Year: 2003
Level of sECP before and after ASIT in asthma and rhinitis patients Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
Add-on omalizumab therapy for patients with severe persistent allergic (IgE-mediated) asthma: identifying which patients to treat and which patients respond Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006
Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Inflammatory profile of patients with allergic asthma & rhinitis versus patients with allergic rhinitis alone Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients Year: 2007
Serum levels of interleukin-18 in patients affected by allergic bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 30s Year: 2002
Baseline inflammation in the lower airways of allergic rhinitic subjects compared to normal subjects Source: Eur Respir J 2001; 18: Suppl. 33, 270s Year: 2001
Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Correlations between cellular and soluble markers in the treatment with new polipeptide RUZAM in patients with allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 368s Year: 2005
The specific methods of immunotherapy in treatment of the patients with allergic seasonal rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Inflammatory markers in induced sputum of patients with allergic rhinitis in relation to exposure to pollen allergens Source: Eur Respir J 2006; 28: Suppl. 50, 444s Year: 2006
Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008
The influence of the allergen-specific immunotherapy (ASIT) against the backdrop of an immunomodulator in patients suffering from seasonal allergic rhinitis (SAR) on the level of cytokines, IgE and IgG. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
Improved disease control in asthmatics treated with daclizumab is not associated with changes in allergen-specific or total IgE Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005
Does allergens influence resistin levels in children with allergic rhinitis? Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012